Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biotechnology company whose news flow centers on the development of orally administered small-molecule drugs targeting the A3 adenosine receptor. On this page, readers can follow company announcements on clinical trial progress, regulatory designations, patent developments, financing events, and corporate actions related to its oncology, liver disease, inflammatory, and sexual dysfunction programs.
Recent news has highlighted pivotal and mid-stage clinical studies, including a Phase III trial of Namodenoson in advanced hepatocellular carcinoma, a Phase IIb trial in MASH, and a Phase IIa study in pancreatic cancer. The company has also reported compassionate use cases in advanced liver disease and cirrhosis, as well as long-term survival outcomes in liver cancer patients treated with Namodenoson. For Piclidenoson, updates include Phase III psoriasis development and protocol preparation for rare diseases such as Lowe Syndrome, along with preclinical findings in vascular dementia models.
News items also cover CF602, an A3AR allosteric modulator in development for erectile dysfunction, including patent allowances and grants in markets such as Brazil, the United States, and Europe. Can-Fite regularly reports on its intellectual property strategy, out-licensing and distribution agreements for human and veterinary indications, participation in industry conferences, and capital markets activities such as public offerings, warrant amendments, and share structure changes like reverse splits and ADS ratio adjustments.
Investors and observers can use this CANF news feed to monitor key milestones that may affect the company’s clinical pipeline, regulatory interactions, partnering discussions, and financial position over time.
Can-Fite BioPharma Ltd. (NYSE American: CANF) has appointed Yossi Borenstein as an External Director during its recent annual general meeting. Borenstein, CEO of Shizim Group and a veteran in the Israeli biomed industry, brings over 35 years of experience, having previously managed Bristol-Myers Squibb (Israel) and served in various leadership roles across multiple organizations. Can-Fite, engaged in developing therapies for cancer, liver, and inflammatory diseases, continues its clinical progress with drug candidates like Piclidenoson and Namodenoson.
Can-Fite BioPharma Ltd (NYSE: CANF) has completed preparatory work for its pivotal Phase III trial of Namodenoson, targeting hepatocellular carcinoma (HCC), the most prevalent liver cancer. The trial will enroll 450 patients globally and is designed to assess overall survival and safety. Both the FDA and EMA have agreed to the trial protocol, and Namodenoson has received Orphan Drug and Fast Track designations. This advancement comes amid a global market for HCC treatments projected to reach $3.8 billion by 2027.
Can-Fite BioPharma (NYSE: CANF) has entered a development and commercialization agreement with Vetbiolix for its drug, Piclidenoson, targeting osteoarthritis in pets. Vetbiolix will conduct proof-of-concept studies over two years, covering all associated costs, and may obtain a license for further development if the data is positive. The canine osteoarthritis market is projected to reach $3 billion by 2024, with the broader companion animal health market expected to grow to $27 billion by 2028. Piclidenoson offers a potentially effective oral treatment alternative to existing NSAIDs.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that the Chinese National Intellectual Property Administration granted a Notice of Allowance for its patent on an A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation. This patent supports their liver drug candidate, Namodenoson, which is set to enter Phase IIb trials for non-alcoholic steatohepatitis (NASH) in Q3 2021, following successful Phase IIa results. Namodenoson has been licensed in China with potential milestone payments of up to $74.5 million. The NASH market in China is projected to reach $6.4 billion by 2027.
Can-Fite BioPharma Ltd (NYSE American: CANF) received clearance from the Israeli Ministry of Health to initiate a Phase IIb study of its drug candidate Namodenoson for treating NASH. Enrollment is expected to start in Q3 2021, earlier than previously anticipated. The study aims to assess Namodenoson's efficacy in 140 subjects, comparing its effects against a placebo over 36 weeks. Given the urgent unmet medical need for NASH treatments, the market for NASH pharmaceuticals could reach $35-40 billion by 2025.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announces that Dr. Sari Fishman will present at the BIO Digital Convention on June 10-11 & 14-18, 2021. Can-Fite has secured approximately $20 million from out-licensing agreements for its drug candidates, with potential milestone payments of up to $130 million. The company anticipates key developments, including topline data from Phase III psoriasis and Phase II COVID-19 trials, as well as initiating pivotal trials in liver cancer and NASH by year-end.
Can-Fite BioPharma Ltd (NYSE American: CANF) reported its financial results for Q1 2021, revealing revenues of $0.15 million, down 25.2% from $0.20 million in Q1 2020. The company secured a $42.7 million out-licensing deal with Ewopharma, including $2.25 million upfront and up to $40.45 million contingent on milestones. The Phase III Comfort™ psoriasis study reached 75% enrollment, with topline results anticipated in Q4 2021. Can-Fite’s R&D expenses declined by 65.5% to $1.30 million, while general and administrative expenses rose to $1.01 million. Future trials for liver cancer and NASH are set for late 2021.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will appear on The RedChip Money Report on May 29th, at 7 p.m. local time, reaching 73 million homes in the U.S. The interview will cover upcoming milestones and updates on Can-Fite's drug pipeline, including Piclidenoson and Namodenoson, which target conditions like psoriasis and liver cancer. Piclidenoson is in Phase III trials for psoriasis and Phase II studies for COVID-19, while Namodenoson has shown promise in treating liver cancer and has received Orphan Drug Designation.
Can-Fite BioPharma Ltd (NYSE American: CANF) will present at Benzinga’s Global SmallCap Conference on May 13, 2021. CEO Dr. Pnina Fishman will discuss the company’s advancements in treating psoriasis, liver cancer, and NASH. Can-Fite's drug candidates are in Phase II and Phase III trials, showcasing clinical proof of concept. The company’s lead drug, Piclidenoson, targets moderate COVID-19, while Namodenoson is set for Phase III for hepatocellular carcinoma and has received Orphan Drug and Fast Track Designation from the FDA.
Can-Fite BioPharma Ltd (NYSE American: CANF) reported that 75% of patients have been enrolled in its Phase III Comfort™ study for Piclidenoson, targeting moderate to severe plaque psoriasis. The study aims to establish the drug's superiority over placebo and non-inferiority to Apremilast, with enrollment expected to finalize in Q3 2021 and topline results anticipated in Q4 2021. The company has received over $20 million from distribution agreements for Piclidenoson, which is out-licensed in several countries. The psoriasis therapeutic market is projected to hit $11.3 billion by 2025.